Literature DB >> 12890705

Diadenosine-5-phosphate exerts A1-receptor-mediated proarrhythmic effects in rabbit atrial myocardium.

B Brandts1, R Borchard, D Dirkmann, I Wickenbrock, B Sievers, M van Bracht, M W Prull, H-J Trappe.   

Abstract

(1) Diadenosine polyphosphates have been described to be present in the myocardium and exert purinergic- and nonreceptor-mediated effects. Since the electrophysiological properties of atrial myocardium are effectively regulated by A(1) receptors, we investigated the effect of diadenosine pentaphosphate (Ap(5)A) in rabbit myocardium. (2) Parameters of supraventricular electrophysiology and atrial vulnerability were measured in Langendorff-perfused rabbit hearts. Muscarinic potassium current (I(K(ACh/Ado))) and ATP-sensitive potassium current (I(K(ATP))) were measured by using the whole-cell voltage clamp method. (3) Ap(5)A prolonged the cycle length of spontaneously beating Langendorff perfused hearts from 225+/-14 (control) to 1823+/-400 ms (Ap(5)A 50 micro M; n=6; P<0.05). This effect was paralleled by higher degree of atrio-ventricular block. Atrial effective refractory period (AERP) in control hearts was 84+/-14 ms (n=6). Ap(5)A>/=1 micro M reduced AERP (100 micro M, 58+/-11 ms; n=6). (4) Extrastimuli delivered to hearts perfused with Ap(5)A- or adenosine (>/= micro M)-induced atrial fibrillation, the incidence of which correlated to the concentration added to the perfusate. The selective A(1)-receptor antagonist CPX (20 micro M) inhibited the Ap(5)A- and adenosine-induced decrease of AERP. Atrial fibrillation was no longer observed in the presence of CPX. (5) The described Ap(5)A-induced effects in the multicellular preparation were enhanced by dipyridamole (10 micro M), which is a cellular adenosine uptake inhibitor. Dipyridamole-induced enhancement was inhibited by CPX. (6) Ap(5)A (</=1 mM) did neither induce I(K(Ado)) nor I(K(ATP)). No effect on activated I(K(Ado/ATP)) was observed in myocytes superfused with Ap(5)A. However, effluents from Langendorff hearts perfused with Ap(5)A 100 micro M activated I(K(Ado)) by using A(1) receptors. (7) Ap(5)A did not activate A(1) receptors in rabbit atrial myocytes. The Ap(5)A induced A(1)-receptor-mediated effects on supraventricular electrophysiology and vulnerability suggest that in the multicellular preparation Ap(5)A is hydrolyzed to yield adenosine, which acts via A(1) receptors. An influence on atrial electrophysiology or a facilitation of atrial fibrillation under conditions resulting in increased interstitial Ap(5)A concentrations might be of physiological/pathophysiological relevance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890705      PMCID: PMC1573956          DOI: 10.1038/sj.bjp.0705361

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels.

Authors:  A J Carrasco; P P Dzeja; A E Alekseev; D Pucar; L V Zingman; M R Abraham; D Hodgson; M Bienengraeber; M Puceat; E Janssen; B Wieringa; A Terzic
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 2.  Mechanisms of adenosine-mediated actions on cellular and clinical cardiac electrophysiology.

Authors:  W K Shen; Y Kurachi
Journal:  Mayo Clin Proc       Date:  1995-03       Impact factor: 7.616

3.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

Review 4.  The effects of diadenosine polyphosphates on the cardiovascular system.

Authors:  N A Flores; B M Stavrou; D J Sheridan
Journal:  Cardiovasc Res       Date:  1999-04       Impact factor: 10.787

5.  Acetylcholine-sensitive muscarinic K+ channels in mammalian ventricular myocytes.

Authors:  S Koumi; J A Wasserstrom
Journal:  Am J Physiol       Date:  1994-05

Review 6.  Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes.

Authors:  L Belardinelli; J C Shryock; Y Song; D Wang; M Srinivas
Journal:  FASEB J       Date:  1995-03       Impact factor: 5.191

7.  Activation of muscarinic K+ current in guinea-pig atrial myocytes by a serum factor.

Authors:  K Banach; J Hüser; P Lipp; M C Wellner; L Pott
Journal:  J Physiol       Date:  1993-02       Impact factor: 5.182

8.  Effect of intravenous adenosine on human atrial and ventricular repolarisation.

Authors:  S O Nunain; C Garratt; V Paul; N Debbas; D E Ward; A J Camm
Journal:  Cardiovasc Res       Date:  1992-10       Impact factor: 10.787

9.  Effects of adenosine on atrial refractoriness and arrhythmias.

Authors:  G Kabell; L V Buchanan; J K Gibson; L Belardinelli
Journal:  Cardiovasc Res       Date:  1994-09       Impact factor: 10.787

Review 10.  G protein regulation of cardiac muscarinic potassium channel.

Authors:  Y Kurachi
Journal:  Am J Physiol       Date:  1995-10
View more
  4 in total

Review 1.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

2.  The effects of caffeine on the inducibility of atrial fibrillation.

Authors:  Abdul Rashid; Mujahid Hines; Benjamin J Scherlag; William S Yamanashi; William Lovallo
Journal:  J Electrocardiol       Date:  2006-08-21       Impact factor: 1.438

3.  Diadenosine tetra- and pentaphosphates affect contractility and bioelectrical activity in the rat heart via P2 purinergic receptors.

Authors:  Ksenia B Pustovit; Vladislav S Kuzmin; Denis V Abramochkin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-17       Impact factor: 3.000

4.  Diadenosine pentaphosphate affects electrical activity in guinea pig atrium via activation of potassium acetylcholine-dependent inward rectifier.

Authors:  Denis V Abramochkin; Viktoria M Karimova; Tatiana S Filatova; Andre Kamkin
Journal:  J Physiol Sci       Date:  2016-12-10       Impact factor: 2.781

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.